When is a pharmacogenomics expert needed in a commercial or regulatory dispute?

A pharmacogenomics expert is needed when liability, patent rights, or payment obligations depend on how genetic variation affects drug response or on the validity of a genetic test. Failure-to-warn and labeling disputes, companion diagnostic patent and licensing litigation, laboratory reimbursement and billing disputes, and development agreement claims involving genomic biomarkers all commonly require this expertise. Early consultation helps counsel identify which scientific literature, labeling history, and assay data will be decisive.

What issues can a pharmacogenomics expert analyze or opine on?

These experts can evaluate gene-drug associations, the evidentiary weight of clinical studies and guidelines, the regulatory history of pharmacogenomic labeling, and the analytical and clinical validity of genotyping assays. They can explain metabolizer phenotypes, drug transporter variation, and the clinical significance of specific test results. In patent and commercial matters, they can also address the state of the art at a given date and whether a test or method performs as claimed.

What qualifications should counsel prioritize when selecting a pharmacogenomics expert?

Counsel should match the expert's published research to the specific gene, drug class, or assay at issue, because pharmacogenomics spans oncology, cardiology, psychiatry, and laboratory science. Peer-reviewed publications, experience with clinical laboratory standards, and familiarity with FDA labeling and guideline development add considerable weight. For disputes involving historical knowledge, an expert who can reliably reconstruct the state of the science at the relevant date is especially valuable.

How can a pharmacogenomics expert support liability, causation, and rebuttal positions?

On liability, the expert establishes what the scientific and regulatory record showed about a gene-drug interaction and when, which frames whether labeling or testing practices were reasonable. On causation, the analysis addresses whether a patient population's genotype plausibly explains an adverse outcome or treatment failure, or whether other factors better account for it. In rebuttal, the expert can expose reliance on weak associations, misapplied phenotype classifications, or assay limitations that undercut an opposing opinion.

How does Round Table Group identify and present the right pharmacogenomics expert for a case?

Round Table Group starts by working with counsel to define the gene-drug question, the regulatory or patent issues, and the type of opinion the case requires. We then source candidates and speak with them directly, assessing whether their research, laboratory, and testimony experience bear directly on those issues. After confirming interest and availability and completing conflict checks, including any ties to manufacturers or laboratories involved, we present counsel with qualified options for evaluation.

Pharmacogenomics Expert Witnesses

Pharmacogenomics has moved from the research laboratory into drug labeling, diagnostic testing, and reimbursement policy, and the disputes have followed. Pharmaceutical manufacturers face claims that labeling failed to address genetic variants affecting drug metabolism, diagnostic companies and drug sponsors contest the scope of patents and licenses covering companion tests, and clinical laboratories litigate with payers over whether genetic testing was medically necessary and properly billed. Collaboration and development agreements generate their own conflicts when a genomic biomarker fails to perform as projected. Across these matters, the central question is what the scientific evidence linking genotype to drug response actually showed at a given time, and what a reasonable sponsor, laboratory, or payer should have done with it.

A pharmacogenomics expert helps counsel separate established gene-drug associations from preliminary or contested findings. The expert can evaluate the strength of published evidence, clinical guidelines, and FDA labeling decisions concerning variants in metabolizing enzymes and drug transporters, and explain how allele frequency, phenotype classification, and assay design affect the clinical meaning of a result. In laboratory and reimbursement disputes, the analysis turns to analytical validity, clinical utility, and whether testing practices conformed to accepted standards. These opinions support or rebut failure-to-warn and causation theories, inform claim construction and infringement analysis for diagnostic patents, and give damages experts a scientifically grounded view of a test's market value.

Because the field sits at the intersection of genetics, pharmacology, and laboratory medicine, the most persuasive expert is one whose research matches the specific gene-drug question before the court. Round Table Group can connect counsel with scholars and researchers from major universities whose work spans cancer genomics, drug transport, pharmacogenetics, and chemical carcinogenesis, along with laboratory medicine specialists in clinical and forensic toxicology who have testified on drug testing and biomarkers. Their publications in pharmaceutical, genomic, and laboratory research provide the foundation needed to address both scientific and regulatory issues under rigorous admissibility scrutiny. Drawing on more than 75,000 expert searches for litigators, we welcome the opportunity to support your pharmacogenomics matter by calling us at (202) 908-4500.

Kinds of Cases We Work On

Round Table Group helps our clients find a wide variety of Pharmacogenomics expert witnesses for cases like:

Pharmacogenomic Test Lab Accuracy Disputed by Insurer.

A health insurer sued a pharmacogenomic testing laboratory alleging a batch of drug-metabolism panels produced unreliable genotype calls, leading to costly downstream prescribing errors across a covered population. We identified experts with experience in pharmacogenomic assay validation, clinical laboratory quality control, and genotype-phenotype interpretation standards. The assay validation expert's proficiency testing review confirmed a reagent lot defect, supporting the insurer's product liability claim.

Companion Diagnostic Partnership Dispute Delays Drug Launch.

A pharmaceutical sponsor sued a diagnostics partner alleging delays in validating a companion diagnostic for a targeted cancer therapy breached the co-development agreement's regulatory submission timeline. We identified experts with experience in companion diagnostic development, pharmacogenomic biomarker validation, and regulatory submission standards. The diagnostic development expert's timeline review found the delays stemmed from the sponsor's late biomarker specification changes, defeating the sponsor's breach claim.

Biomarker Patent Licensing Royalty Dispute Reaches Arbitration.

A genomics company and a pharmaceutical licensee arbitrated a royalty dispute after the licensee expanded use of a patented pharmacogenomic biomarker into a new drug indication beyond the original license's field of use. We identified experts with experience in pharmacogenomic patent licensing, biomarker field-of-use analysis, and royalty accounting. The licensing expert's field-of-use analysis found the expanded use exceeded the licensed scope, resulting in an arbitration award for additional royalties.

CRO Genomic Data Mishandling Disputed by Sponsor.

A pharmaceutical sponsor sued a contract research organization alleging mishandled pharmacogenomic sample data at several trial sites compromised the genotype-stratified efficacy analysis for a drug candidate. We identified experts with experience in pharmacogenomic clinical trial design, sample chain of custody, and good clinical practice compliance. The clinical trials expert's chain-of-custody audit confirmed the mishandling, supporting the sponsor's claim for site remediation costs.

PBM Disputes Pharmacogenomic Test Reimbursement Rate Policy.

A diagnostics company sued a pharmacy benefit manager alleging a reimbursement rate reduction for pharmacogenomic drug-interaction testing violated the terms of their network participation agreement. We identified experts with experience in pharmacogenomic health economics, pharmacy benefit reimbursement policy, and healthcare contract interpretation. The health economics expert's cost-effectiveness analysis supported the diagnostics company's rate claim, resulting in a favorable arbitration award.

Genomic Test Kit Defect Alleged by Distributor.

A diagnostics distributor sued a pharmacogenomic test kit manufacturer alleging a batch of kits produced inconsistent genotype results across a multi-state clinical rollout. We identified experts with experience in genomic assay manufacturing, pharmacogenomic test kit quality control, and molecular diagnostics engineering. The manufacturing quality expert's batch audit confirmed a reagent stability defect, supporting the distributor's product liability claim.

EHR Vendor Sued Over Pharmacogenomic Alert Failure.

A hospital system sued its electronic health records vendor alleging a software defect suppressed critical pharmacogenomic drug-interaction alerts across several clinical modules, breaching their implementation agreement's functionality warranties. We identified experts with experience in clinical decision support systems, pharmacogenomic alert logic, and health IT software quality assurance. The clinical decision support expert's system audit confirmed the alert suppression defect, supporting the hospital's breach of warranty claim.

Academic Lab Disputes Pharmacogenomic Data Licensing Scope.

A university research lab and a diagnostics company disputed licensing terms after the company incorporated the lab's pharmacogenomic variant database into a commercial product beyond the agreed noncommercial research scope. We identified experts with experience in genomic database licensing, pharmacogenomic research data governance, and academic-industry technology transfer. The technology transfer expert's usage audit confirmed the commercial use exceeded the license, supporting the lab's breach of contract claim.

DTC Genomics Firm Disputes Lab Data Quality.

A direct-to-consumer genomics company sued its outsourced sequencing laboratory alleging a systematic pipeline error produced inaccurate pharmacogenomic drug-response reports for a significant share of processed customer samples. We identified experts with experience in genomic sequencing quality control, bioinformatics pipeline validation, and pharmacogenomic report generation standards. The bioinformatics expert's pipeline audit confirmed the error, supporting the genomics company's claim for cost recovery.

Genomic Database Vendor Disputes API Usage Limits.

A pharmacogenomic database vendor and a drug developer disputed API usage fees after the developer's automated variant-lookup queries allegedly exceeded the contracted call volume across a clinical decision support integration. We identified experts with experience in genomic database licensing, API usage auditing, and pharmacogenomic informatics systems. The informatics expert's log analysis found the query volume stayed within contracted limits, defeating the vendor's claim for additional fees.

Put Our Pharmacogenomics Expert Network to Work for You

Our huge network of experts – eminent university professors and practitioners who have achieved renown as thought leaders in their fields – combined with unparalleled research capabilities puts the experts you need at your disposal when and where you need them.

If you’re a litigator or general counsel, we want to put this network to work for you and your clients. Let us know how we can help by calling us at (202) 908-4500 or filling out the form on this page. We’re so confident you’ll love what we do that unless you retain an expert we present there’s no charge!

GET STARTED FINDING THE RIGHT EXPERT WITNESS

Spend your time working with your experts, not searching for them! We're here to de-stress the process of having a great expert witness team so that it’s easy to have the right experts every time. We'll conduct a quick but thorough search and deliver a roster of top candidates for you to review. There's no charge for the custom search — you pay only the hourly rate if you retain one of our experts.

Or call 202-908-4500 or email us.

Expert Services For Litigators +

For Experts +

About Us +

Resources +

Request An Expert